05.10.2017 • NewsElaine BurridgeErgomedorphan drug

Ergomed Buys Dutch-based PSR Group

(c) totojang1977/Shutterstock
(c) totojang1977/Shutterstock

UK pharmaceutical company Ergomed has acquired PSR Group, a Dutch contract research organization (CRO) that specializes in orphan drug development and is regarded as a leading expert in rare diseases, for a total price of €5.7 million.

Under the terms of the transaction, Ergomed has made an initial payment of €3.2 million with a further sum of up to €2.5 million contingent upon achieving EBITDA targets in 2017, 2018 and 2019.

Ergomed said it would continue to grow the business under the PSR brand and remain focused on the two divisions - PSR Orphan Experts, which supports biotech and pharma companies with their regulatory and clinical development of orphan drugs, and PSR Pharma Resource, a niche staffing provider focused on orphan drug specialists.

Ergomed’s CEO, Dan Weng, said the acquisition fits with its strategy of becoming a leader in orphan drug development. PSR’s CEO, Roger Legtenberg added that it welcomed the opportunity to expand its portfolio and geographical coverage by leveraging Ergomed’s international reach and complementary services.

According to Ergomed, there is a total of 30 million people worldwide suffering from rare diseases. Consequently, the orphan drug market to target these diseases continues to grow, requiring highly specialized providers because of the regulatory, logistical and operational complexities of conducting clinical trials.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.